Table 2 Demographics of the human post-mortem cases included in this study. Positivity for astrocytic aSyn was assessed using the antibodies LASH-BL 34-45 or LASH-EGT nY39
Case ID | Gender (m/f) | Age at diagnosis (y) | Age at death (y) | Disease duration (y) | Postmortem delay (h) | Braak stage (LB-type) | Braak stage (AD-type) | Astrocytic aSyn detection | ||
|---|---|---|---|---|---|---|---|---|---|---|
cing | EC | amg | ||||||||
PD1 | m | 66 | 78 | 12 | 32 | 6 | 4 | + | + | + |
PD2 | m | 73 | 82 | 9 | 55 | 6 | 1 | + | − | + |
PD3 | m | 87 | 92 | 5 | 36 | 6 | 1 | + | + | + |
PD4 | m | 57 | 80 | 23 | na | 5 | 1 | + | + | + |
PD5 | m | 73 | 79 | 6 | 72 | 5 | 2 | + | − | − |
PD6 | m | 63 | 69 | 6 | 72 | 5 | 2 | + | + | + |
PD7 | m | 55 | 75 | 20 | 88.5 | 6 | 1 | + | − | − |
PD8 | m | 80 | 89 | 8.5 | 26 | 6 | 4 | − | na | na |
PD9 | m | 60 | 84 | 24 | 71 | 6 | 2 | + | na | na |
PDD1 | m | 54 | 72 | 18 | 90 | 6 | 1 | + | + | + |
PDD2 | m | 71 | 80 | 9 | 64 | 6 | 3 | + | + | + |
PDD3 | m | 83 | 92 | 9 | 24 | 5 | 1 | − | − | + |
PDD4 | m | 77 | 91 | 14 | 72 | 6 | 2 | + | − | + |
PDD5 | m | 77 | 92 | 14 | 41 | 6 | 3 | + | + | + |
PDD6 | m | 61 | 80 | 19 | 66 | 6 | 2 | + | na | na |
DLB1 | f | 78 | 89 | 11.4 | 63 | 6 | 3 | + | + | + |
DLB2 | m | 62 | 72 | 10 | 48 | 6 | 1 | na | + | na |
DLB3 | m | 83 | 87 | 4 | 48 | 6 | 2 | + | na | na |
SNCA G51D1 | m | 19 | 49 | 30 | 43 | na | na | + | + | na |
SNCA G51D2 | f | 69 | 75 | 6.5 | 62 | na | 1 | + | + | na |
SNCA G51D3 | m | 45 | 52 | 6.5 | 85.3 | na | 1 | + | + | + |
SNCA duplication | m | 55 | 62 | 6.9 | 143 | 6 | 2 | + | + | + |
MSA1 | f | 58 | 65 | 7.4 | 55 | 0 | 0 | na | na | na |
MSA2 | m | 67 | 74 | 6.6 | 22 | 0 | 3 | na | na | na |
MSA3 | f | 46 | 52 | 6 | 78 | 0 | 1 | na | na | na |
CTR1 | f | na | 89 | na | 24 | 0 | 2 | − | − | − |
CTR2 | m | na | 80 | na | 48 | 0 | 2 | − | − | − |
CTR3 | f | na | 89 | na | 24 | 0 | 2 | − | − | − |